Advertisement


Roy S. Herbst, MD, PhD, on Results From SWOG S0819

2015 IASLC World Conference on Lung Cancer

Advertisement

Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in advanced non–small cell lung cancer (Abstract PLEN04.01).



Related Videos

Lung Cancer

James L. Mulshine, MD, on Lung Cancer Screening in the United States: Can It Happen?

James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice early lung cancer detection in the target population of tobacco-exposed individuals (Abstract MS 15.01).

Lung Cancer

Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease

Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or docetaxel (Abstracts ORAL 31.01, 31.02, and 31.03).

Lung Cancer

Jennifer King, PhD: Scientific Perspectives From the Lung Cancer Alliance

Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.

Lung Cancer

Howard Jack West, MD, on New Kinase Targets for Treating Advanced NSCLC

Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of sensitivity to afatinib or neratinib (Abstracts ORAL 3.01, 3.02, and 3.03).

Lung Cancer

Christine D. Berg, MD, on Screening for Lung Cancer in Those at High Risk

Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening will help improve the prognosis of patients with lung cancer (Abstract PLEN 01.01).

Advertisement

Advertisement




Advertisement